DUBLIN--(BUSINESS WIRE)--The "United States Molecular Diagnostics Market, Test Volume Forecast & Companies: Oncology Test (Breast, Colorectal, Prostate) Infectious Diseases Test (Virology, HPV, HAI, Critical Care) Genetic Test (Blood Screening, Food Pathogen, Tissue Typing HLA)" report has been added to Research and Markets' offering
By 2024, the United States molecular diagnostics market is expected to cross US$ 9 billion
Main factors pouring the growth of molecular diagnostics market are increased incidence of infectious diseases and different types of cancer. On the other hand, advancement of new technologies in the field of medicine and research fuels the molecular diagnostics market.
A diagnosis based on symptoms and use of substitute markers is replaced by the genomic and the proteomic analysis. Molecular diagnostics system is one of the promising systems which can transform disease diagnosis. It offers the assurance for early disease detection, potentially before symptoms have even occurred.
Molecular oncology tests have emerged as a substantial market segment. Today in the field of medical diagnostics, molecular diagnostics for cancer testing offers one of the key areas for innovation and expansion. The United States leads the regional market for blood screening and blood products. Molecular diagnostics is also a significant tool for Food Pathogen Detection Testing and HLA Testing as well as other diseases.
This report describes the players and in-depth analysis of these players, the players who played a very vital role in the development of molecular diagnostics in the United State are Roche, Hologic, Becton Dickinson, Myraid Genetics, Qiagen, Abbott, Siemens, bioMrieux and Cepheid.
This 146 page report with 87 Figures and 4 Tables studies the United States Molecular Diagnostics from 4 view points:
1) Molecular Diagnostics Market and Forecast
2) Segments Market & Forecast
3) Segments Test Volume & Forecast
4) Company Molecular Diagnostics Sales & Forecast
United States Molecular Diagnostics Market & Test Volume - Application Segment Analysis (2010 - 2024):
-
Oncology Test
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Others
-
Infectious Diseases
- Virology Test
- HPV Test
- HAI Test
- Critical Care Test
-
Genetic Test
- Blood Screening
- Food Pathogen Test
- Tissue Typing (HLA Test)
Company Sales Analysis (2010 - 2024):
1. Roche
2. Abbott
3. Myriad Genetics
4. BioMerieux
5. Qiagen
6. Hologic Inc.
7. Becton Dickinson
8. Siemens
9. Cepheid
10. Others
For more information about this report visit https://www.researchandmarkets.com/research/gzf9pt/united_states
